Plant Name: Apium graveolens
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NPSR1; CXCR1; | |
| ADORA2A; HTR2C; DRD4; | |
| RECQL; TDP1; PLA2G1B; PKM; PIK3R1; GLO1; MPO; HSD17B1; AKR1B1; HSD17B2; HSD17B10; ALOX15; ALDH1A1; ALOX12; NOX4; USP2; TNKS; PARP1; TNKS2; PYGL; POLB; CD38; | |
| ACHE; | |
| CFTR; | |
| NEK6; PKN1; AKT1; MET; CAMK2B; CSNK2A1; DAPK1; SYK; AXL; NEK2; FLT3; SRC; IGF1R; PTK2; AURKB; GSK3B; KDR; CDK1; MAPK1; PIM1; NUAK1; ALK; CDK6; | |
| CA14; CA3; CA7; CA5A; CA12; CA9; CA4; CA6; CA2; CA1; | |
| AR; | |
| ESR1; ESR2; | |
| KDM4E; | |
| MAOA; ALOX5; PTGS2; XDH; | |
| MMP13; MMP12; MMP3; MMP2; MMP9; | |
| BACE1; | |
| STAT6; HIF1A; NFKB1; TP53; | |
| ABCC1; ABCG2; | |
| LMNA; MAPT; THPO; NPC1; APP; TTR; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
| Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
| Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
| Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 5.973E-13 | 2.242E-10 | ADORA2A, AURKB, CA2, CA7, CFTR, HIF1A, MAPK1, NEK2, NPC1, NPSR1, PLA2G1B, PTGS2, SYK, TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.281E-12 | 4.290E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2D6, CYP3A4, NOX4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.408E-12 | 7.598E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2D6, CYP3A4, MPO, NOX4, PTGS2, SRC |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.182E-11 | 3.299E-09 | ABCG2, ACHE, ADORA2A, AKT1, ALK, APP, CAMK2B, CD38, CSNK2A1, DAPK1, DRD4, ESR1, ESR2, FLT3, IGF1R, KDR, MAPK1, MAPT, MET, MMP9, NFKB1, PARP1, PKM, PTGS2, PYGL, SMN1, SMN2, STAT6, TP53, TTR, USP2, XDH |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.717E-11 | 4.559E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 2.770E-11 | 7.095E-09 | ABCC1, ABCG2, AKT1, ALK, AURKB, AXL, CAMK2B, CDK1, CDK6, CFTR, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, KDR, MAPK1, MET, NEK2, NEK6, NUAK1, PIM1, PKM, PKN1, PTK2, PYGL, RECQL, SRC, SYK, TP53 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.418E-11 | 8.457E-09 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2D6, CYP3A4, XDH |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 7.165E-10 | 1.311E-07 | AR, CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9, ESR1, ESR2, GLO1, MMP12, MMP13, MMP2, MMP3, MMP9, PARP1, TNKS, TP53 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 7.886E-10 | 1.431E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8 |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 8.330E-10 | 1.487E-07 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, MAPK1, NEK6, PKN1, SRC, SYK, TNKS |
| MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 1.222E-09 | 2.031E-07 | AKT1, ALK, AURKB, CAMK2B, CDK1, CDK6, CSNK2A1, DAPK1, GSK3B, MAPK1, NEK2, NEK6, NUAK1, PIM1, PKN1, SYK |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 6.235E-09 | 8.278E-07 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, MAPK1, PKN1, TNKS |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 9.661E-09 | 1.223E-06 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 1.882E-08 | 2.203E-06 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 6.089E-08 | 6.468E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.114E-07 | 2.790E-05 | CYP1A2, CYP2C19, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 3.114E-07 | 2.790E-05 | CYP1A2, CYP2C8, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 5.205E-07 | 4.376E-05 | CYP1A2, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0031324; negative regulation of cellular metabolic process | 5.618E-07 | 4.659E-05 | ADORA2A, AKT1, APP, AR, AURKB, CD38, CDK1, CSNK2A1, CYP2D6, DAPK1, DRD4, ESR1, ESR2, GSK3B, HIF1A, IGF1R, MAPT, MET, MMP12, MMP3, MMP9, NFKB1, NPC1, PARP1, PKN1, PTGS2, SRC, STAT6, TNKS, TNKS2, TP53, USP2, XDH |
| BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 7.899E-07 | 6.347E-05 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.127E-06 | 8.733E-05 | ALOX12, ALOX15, ALOX5, PTGS2 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 1.207E-06 | 9.158E-05 | HIF1A, MMP12, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.227E-06 | 9.276E-05 | ADORA2A, CA2, CA7, HTR2C, KDR, NPSR1, PARP1, PLA2G1B, SRC |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.296E-06 | 9.767E-05 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 1.984E-06 | 1.421E-04 | AR, CDK1, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 2.006E-06 | 1.428E-04 | MMP12, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 2.348E-06 | 1.644E-04 | ALOX15, ESR1, GSK3B, MAPT, MET, MMP3, PARP1, SRC, TP53 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 2.583E-06 | 1.786E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0032502; developmental process | GO:0007568; aging | 2.913E-06 | 1.995E-04 | AKT1, AURKB, CDK1, CYP1A1, MPO, NOX4, POLB, PTGS2, TP53 |
| BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 3.353E-06 | 2.260E-04 | ACHE, ADORA2A, CD38, CFTR, HIF1A, MMP12, PLA2G1B, SRC, SYK |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 4.131E-06 | 2.677E-04 | IGF1R, KDR, PTK2, SRC, SYK |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 5.252E-06 | 3.325E-04 | HIF1A, MMP12, MMP13, MMP2, MMP3, MMP9 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 5.252E-06 | 3.325E-04 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1 |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 6.842E-06 | 4.208E-04 | AKT1, MAPT, NOX4, PTGS2, TP53, XDH |
| BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 8.873E-06 | 5.367E-04 | ALK, CDK1, DRD4, MAPK1, PKN1, PLA2G1B, SYK |
| BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 1.041E-05 | 6.191E-04 | PARP1, SRC, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 1.041E-05 | 6.191E-04 | APP, GSK3B, IGF1R, PARP1 |
| BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 1.073E-05 | 6.330E-04 | ADORA2A, APP, MAPT |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 1.131E-05 | 6.623E-04 | AKR1B1, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, APP, AR, AURKB, CA1, CA2, CA3, CA7, CAMK2B, CDK1, CDK6, CFTR, CSNK2A1, FLT3, GLO1, GSK3B, HIF1A, HSD17B1, LMNA, MAPK1, MAPT, NEK2, NEK6, NFKB1, PIK3R1, PIM1, PKM, PKN1, PLA2G1B, PTK2, PYGL, SMN1, SMN2, SRC, STAT6, SYK, TNKS, TNKS2, TP53, XDH |
| BP | GO:0051179; localization | GO:0034502; protein localization to chromosome | 1.284E-05 | 7.437E-04 | AURKB, CDK1, ESR1, TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 1.322E-05 | 7.596E-04 | AXL, MET, NOX4, PIK3R1, PTK2, SRC, THPO |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.514E-05 | 8.540E-04 | AKR1B1, AXL, CDK1, CYP1B1, STAT6 |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 1.527E-05 | 8.591E-04 | CA2, CA7, CFTR |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.574E-05 | 8.811E-04 | AKT1, HIF1A, LMNA, PTGS2, SRC, TP53 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.837E-05 | 1.015E-03 | AKT1, CYP1A2, MAPK1, MMP9 |
| BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 2.068E-05 | 1.131E-03 | MMP12, MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 2.092E-05 | 1.136E-03 | AR, CYP19A1, ESR1 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 2.091E-05 | 1.136E-03 | CSNK2A1, HIF1A, KDR, MAPT |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 2.168E-05 | 1.168E-03 | AKT1, AXL, MAPK1, PIK3R1, SRC, SYK |
| BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 2.507E-05 | 1.338E-03 | AKT1, ALOX12, APP, AR, AXL, CA2, CAMK2B, CDK1, CDK6, CYP1B1, ESR1, GSK3B, HIF1A, KDR, MAPT, PIK3R1, PIM1, PTGS2, PTK2, SRC, STAT6, SYK, THPO, XDH |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 2.600E-05 | 1.371E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 2.600E-05 | 1.371E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 2.600E-05 | 1.371E-03 | ALOX12, ALOX15 |
| CC | GO:0044464; cell part | GO:0005739; mitochondrion | 2.648E-05 | 1.392E-03 | AKT1, CA5A, CDK1, CYP1A1, CYP1B1, CYP2D6, ESR2, GSK3B, HSD17B10, MAOA, MAPK1, MMP2, MPO, NFKB1, NOX4, PARP1, PKM, SRC, TP53 |
| BP | GO:0008283; cell proliferation | GO:0033598; mammary gland epithelial cell proliferation | 2.778E-05 | 1.454E-03 | ESR1, MAPK1, STAT6 |
| BP | GO:0065007; biological regulation | GO:0045124; regulation of bone resorption | 3.372E-05 | 1.727E-03 | CA2, CD38, SRC, SYK |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 3.405E-05 | 1.728E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 3.598E-05 | 1.810E-03 | CYP19A1, HSD17B1, HSD17B2 |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 3.598E-05 | 1.810E-03 | ADORA2A, CA2, CA7 |
| BP | GO:0007610; behavior | GO:0007626; locomotory behavior | 3.792E-05 | 1.889E-03 | ADORA2A, ALK, APP, DRD4, HTR2C, NPC1, USP2 |
| BP | GO:0050896; response to stimulus | GO:0001101; response to acid chemical | 4.131E-05 | 2.036E-03 | AKR1B1, AKT1, CD38, HSD17B2, KDR, MMP2, PTGS2, SRC, TP53 |
| BP | GO:0009987; cellular process | GO:0010639; negative regulation of organelle organization | 4.334E-05 | 2.125E-03 | AKT1, LMNA, MAPT, MET, NEK2, PARP1, SRC, TNKS, TNKS2 |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 4.424E-05 | 2.155E-03 | AXL, CDK1, CSNK2A1, FLT3, PKM |
| BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 4.424E-05 | 2.155E-03 | AKR1B1, AKT1, MMP2, MMP9, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0090407; organophosphate biosynthetic process | 4.544E-05 | 2.203E-03 | ACHE, ADORA2A, ALOX15, CSNK2A1, HTR2C, MAPK1, PIK3R1, PKM, PLA2G1B, PTGS2, PYGL |
| BP | GO:0032502; developmental process | GO:0060065; uterus development | 4.563E-05 | 2.203E-03 | CYP19A1, ESR1, SRC |
| BP | GO:0032502; developmental process | GO:0045597; positive regulation of cell differentiation | 5.082E-05 | 2.432E-03 | AKT1, APP, AR, AXL, CA2, CAMK2B, HIF1A, HTR2C, KDR, MAPT, NFKB1, PARP1, PTGS2, SYK, THPO |
| BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 5.332E-05 | 2.530E-03 | MMP12, MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 6.013E-05 | 2.804E-03 | AKR1B1, AKT1, AR, CFTR, SRC |
| BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 6.461E-05 | 2.993E-03 | ADORA2A, AKT1, CYP1B1, DAPK1, GSK3B, MAPT, MMP9, NOX4, PTGS2, SRC, TP53, XDH |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 6.956E-05 | 3.161E-03 | ALOX15, APP, HTR2C, KDR, NOX4, SRC, THPO |
| BP | GO:0032501; multicellular organismal process | GO:0043536; positive regulation of blood vessel endothelial cell migration | 7.530E-05 | 3.395E-03 | AKT1, HIF1A, KDR, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 7.775E-05 | 3.448E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 7.775E-05 | 3.448E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 7.775E-05 | 3.448E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 7.775E-05 | 3.448E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 7.775E-05 | 3.448E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 7.775E-05 | 3.448E-03 | ALOX12, ALOX15 |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 7.859E-05 | 3.478E-03 | AKR1B1, AKT1, ALOX5, AR, AURKB, CAMK2B, CDK1, CDK6, CSNK2A1, ESR1, ESR2, GSK3B, HIF1A, LMNA, MAPK1, NEK2, NEK6, NFKB1, NUAK1, PARP1, PIM1, PKN1, POLB, RECQL, SMN1, SMN2, SRC, STAT6, TNKS, TP53, USP2 |
| BP | GO:0050896; response to stimulus | GO:0006954; inflammatory response | 7.897E-05 | 3.488E-03 | ADORA2A, AKT1, ALOX15, AXL, CXCR1, NFKB1, NOX4, POLB, PTGS2, SYK |
| BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 8.232E-05 | 3.614E-03 | AKT1, LMNA, MMP9, TP53 |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 8.429E-05 | 3.686E-03 | AURKB, CDK1, PKN1 |
| BP | GO:0008152; metabolic process | GO:0006066; alcohol metabolic process | 8.743E-05 | 3.808E-03 | AKR1B1, ALDH1A1, APP, CFTR, CYP1B1, CYP3A4, NPC1, TTR |
| BP | Unclassified; | GO:0032845; negative regulation of homeostatic process | 9.805E-05 | 4.228E-03 | CD38, HTR2C, PARP1, SRC, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:0014074; response to purine-containing compound | 1.058E-04 | 4.517E-03 | ADORA2A, APP, CFTR, NOX4, PTGS2, TP53 |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 1.066E-04 | 4.541E-03 | AXL, CSNK2A1, DRD4, ESR1, GSK3B, SRC, TP53, USP2 |
| BP | GO:0009987; cellular process | GO:0051983; regulation of chromosome segregation | 1.285E-04 | 5.310E-03 | AURKB, CSNK2A1, NEK2, NEK6, TNKS |
| BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 1.285E-04 | 5.310E-03 | AKT1, HIF1A, MMP9, PTGS2, SRC |
| CC | GO:0016020; membrane | GO:0045121; membrane raft | 1.321E-04 | 5.440E-03 | APP, BACE1, KDR, MAPK1, NPC1, PTGS2, SRC, STAT6 |
| CC | GO:0016020; membrane | GO:0098590; plasma membrane region | 1.365E-04 | 5.607E-03 | ABCC1, ABCG2, ADORA2A, CA2, CA4, CA9, CFTR, MAPK1, MAPT, MET, NOX4, PTGS2, PTK2, SRC, TSHR |
| BP | GO:0065007; biological regulation | GO:0048167; regulation of synaptic plasticity | 1.418E-04 | 5.770E-03 | ADORA2A, APP, CAMK2B, CD38, MAPK1, PTGS2 |
| BP | GO:0065007; biological regulation | GO:0051100; negative regulation of binding | 1.469E-04 | 5.944E-03 | AURKB, CYP2D6, GSK3B, MET, NEK2, TNKS |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 1.550E-04 | 6.170E-03 | TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.550E-04 | 6.170E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.550E-04 | 6.170E-03 | ESR1, ESR2 |
| MF | GO:0005488; binding | GO:0005497; androgen binding | 1.550E-04 | 6.170E-03 | ALDH1A1, AR |
| BP | GO:0050896; response to stimulus | GO:0071498; cellular response to fluid shear stress | 1.624E-04 | 6.419E-03 | CA2, PTGS2, SRC |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.624E-04 | 6.419E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0022610; biological adhesion | GO:0045785; positive regulation of cell adhesion | 1.676E-04 | 6.601E-03 | AKT1, ALOX12, ALOX15, CDK6, GSK3B, KDR, PIK3R1, SRC, SYK |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 1.687E-04 | 6.630E-03 | NOX4, PARP1, POLB, TP53 |
| BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 1.880E-04 | 7.271E-03 | AKT1, AR, DAPK1, LMNA, SRC |
| BP | GO:0009987; cellular process | GO:0000226; microtubule cytoskeleton organization | 1.901E-04 | 7.312E-03 | AURKB, CDK1, LMNA, MAPT, NEK2, NEK6, PTK2, TNKS |
| BP | GO:0008152; metabolic process | GO:0045862; positive regulation of proteolysis | 1.953E-04 | 7.459E-03 | AKT1, APP, CDK1, DAPK1, GSK3B, MAPT, PTK2, SRC, XDH |
| MF | GO:0005488; binding | GO:0046983; protein dimerization activity | 2.121E-04 | 8.061E-03 | ABCG2, ACHE, ADORA2A, AKT1, AR, AXL, CAMK2B, FLT3, HIF1A, MAPT, NFKB1, PIK3R1, PTGS2, PYGL, TP53, TTR, XDH |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.147E-04 | 8.130E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0002376; immune system process | GO:0048534; hematopoietic or lymphoid organ development | 2.203E-04 | 8.298E-03 | FLT3, HIF1A, KDR, MAPK1, PKN1, POLB |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 2.346E-04 | 8.777E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
| BP | GO:0009987; cellular process | GO:1901990; regulation of mitotic cell cycle phase transition | 2.393E-04 | 8.908E-03 | AKT1, APP, AURKB, CDK1, CDK6, CYP1A1, NEK2, NEK6, TP53 |
| BP | GO:0002376; immune system process | GO:0002683; negative regulation of immune system process | 2.393E-04 | 8.908E-03 | ADORA2A, ALOX15, AXL, CDK6, CYP19A1, MMP12, PIK3R1, PKN1, STAT6 |
| CC | GO:0044464; cell part | GO:0034774; secretory granule lumen | 2.460E-04 | 9.095E-03 | ALOX5, APP, MAPK1, MPO, NFKB1, PKM, PYGL, TTR |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 2.475E-04 | 9.133E-03 | CAMK2B, CDK1, CFTR, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2D6, CYP3A4, HSD17B2, NOX4, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 2.574E-04 | 9.390E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.305E-20 | 1.004E-16 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.413E-16 | 2.766E-13 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9, CFTR |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 2.847E-14 | 1.674E-11 | ADORA2A, AURKB, CA2, CA7, CD38, CDK6, CFTR, HIF1A, HTR2C, KDR, MAPK1, NEK2, NPC1, NPSR1, PARP1, PLA2G1B, PTGS2, SRC, SYK, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.413E-13 | 6.279E-11 | CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.046E-19 | 2.008E-17 | CA12; CA1; CA3; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.399E-12 | 1.343E-10 | CAMK2B; SRC; MMP2; PIK3R1; HIF1A; ESR1; MMP9; PTK2; IGF1R; KDR; AKT1; MAPK1; TP53; MET |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.025E-11 | 4.921E-10 | GSK3B; FLT3; DAPK1; MMP2; PIK3R1; PTGS2; HIF1A; MMP9; NFKB1; PTK2; IGF1R; AR; CDK6; AKT1; MAPK1; MET; TP53 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 8.590E-12 | 4.921E-10 | APP; CYP2C8; CYP2D6; MAOA; ALOX5; ALOX15; HTR2C; MAPK1; ALOX12; CYP2C19; PTGS2 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.223E-10 | 4.695E-09 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1; PTGS2; CYP19A1; IGF1R |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 2.493E-09 | 6.839E-08 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; ESR1; NFKB1; ESR2 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.387E-09 | 4.437E-08 | PKM; FLT3; AKT1; MAPK1; PIK3R1; TP53; MET; HIF1A |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.356E-08 | 2.507E-07 | GSK3B; SYK; PIK3R1; PTK2; NFKB1; IGF1R; CDK6; KDR; AKT1; MAPK1; PKN1; TP53; MET |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.373E-08 | 2.507E-07 | GSK3B; AR; AKT1; MAPK1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 2.059E-08 | 3.295E-07 | SRC; KDR; AKT1; MAPK1; PIK3R1; PTGS2; PTK2 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 3.233E-08 | 4.139E-07 | CAMK2B; CDK6; AKT1; MAPK1; PIK3R1; TP53; IGF1R |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 3.197E-08 | 4.139E-07 | SRC; MMP2; AKT1; MAPK1; PIK3R1; ESR1; MMP9; ESR2 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.312E-08 | 3.414E-07 | CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; CYP2C19; PTGS2 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 4.551E-08 | 5.462E-07 | CDK6; SRC; AKT1; MAPK1; STAT6; PIK3R1; TP53; MMP9; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 7.246E-08 | 7.322E-07 | POLB; CDK6; PKM; SYK; SRC; CDK1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.436E-08 | 2.507E-07 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 5.467E-09 | 1.312E-07 | CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 6.029E-08 | 6.431E-07 | CDK6; AKT1; MAPK1; PIK3R1; TP53; MET; IGF1R |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.265E-07 | 1.214E-06 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; TP53; ESR1; HIF1A |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 5.599E-07 | 3.981E-06 | PLA2G1B; MAOA; ALOX15; AKR1B1; ALOX12; PYGL; PTGS2; CYP2C19; CYP3A4; CYP19A1; HSD17B10; CYP2C8; PKM; HSD17B1; ALOX5; HSD17B2; CYP1A2; ALDH1A1; CYP1A1; CD38; XDH |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 2.484E-07 | 2.073E-06 | CAMK2B; GSK3B; SRC; AKT1; MAPK1; PIK3R1; PTK2 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 2.293E-07 | 2.001E-06 | CDK6; AKT1; PIK3R1; PTGS2; TP53; NFKB1; PTK2 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 4.933E-08 | 5.571E-07 | DAPK1; SRC; MMP2; MAPK1; MMP9; TP53 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 2.738E-07 | 2.190E-06 | FLT3; MMP3; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 7.229E-07 | 4.786E-06 | GSK3B; SYK; CSNK2A1; CDK1; AKT1; CD38; PIK3R1; TP53; NFKB1 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 7.229E-07 | 4.786E-06 | GSK3B; SRC; KDR; AKT1; MAPK1; PIK3R1; MET; PTK2; IGF1R |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.649E-07 | 1.507E-06 | CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 3.355E-07 | 2.577E-06 | ALK; CDK6; AKT1; MAPK1; PIK3R1; TP53 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 3.735E-07 | 2.758E-06 | FLT3; PIM1; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 7.896E-07 | 5.053E-06 | CAMK2B; AKT1; MAPK1; PIK3R1; HIF1A; NFKB1; IGF1R |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.233E-06 | 7.173E-06 | MMP3; AKT1; MAPK1; PIK3R1; PTGS2; MMP9; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 2.178E-06 | 1.149E-05 | ABCC1; CDK6; PIM1; CYP1B1; MAPK1; PTGS2; TP53; MMP9; MET; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 9.022E-07 | 5.588E-06 | CDK6; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 2.214E-06 | 1.149E-05 | CAMK2B; GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 4.166E-06 | 2.105E-05 | GSK3B; CXCR1; SRC; AKT1; MAPK1; PIK3R1; NFKB1; PTK2 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.644E-06 | 9.018E-06 | GSK3B; SYK; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 6.167E-06 | 2.888E-05 | PARP1; LMNA; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.644E-06 | 9.018E-06 | CDK6; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 5.093E-06 | 2.507E-05 | GSK3B; CDK6; CSNK2A1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 6.588E-06 | 3.012E-05 | CAMK2B; ADORA2A; AKT1; MAPK1; PIK3R1; CFTR; NFKB1; TSHR |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.176E-06 | 7.057E-06 | CYP2C8; MAOA; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 1.011E-05 | 4.514E-05 | ADORA2A; SRC; KDR; AKT1; MAPK1; PIK3R1; MET; IGF1R |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.095E-05 | 4.777E-05 | MMP2; PIM1; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.717E-05 | 7.158E-05 | PLA2G1B; KDR; AKT1; MAPK1; PIK3R1; MET; NFKB1; IGF1R |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.926E-05 | 1.146E-04 | ABCC1; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 5.215E-05 | 1.889E-04 | GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.352E-04 | 4.475E-04 | CAMK2B; SRC; CD38; MAPK1; PIK3R1; PTGS2 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 5.801E-06 | 2.784E-05 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 1.267E-04 | 4.266E-04 | CDK1; AKT1; MAPK1; PIK3R1; IGF1R |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 1.267E-04 | 4.266E-04 | CAMK2B; SRC; HTR2C; ALOX12; PIK3R1 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.040E-04 | 3.630E-04 | AKT1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.389E-05 | 5.926E-05 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.889E-04 | 5.945E-04 | BACE1; APP; GSK3B; MAPK1; MAPT; HSD17B10 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.889E-05 | 7.554E-05 | AKT1; MAPK1; PIK3R1; MET; HIF1A |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 9.884E-05 | 3.514E-04 | SYK; CSNK2A1; PARP1; PTGS2; NFKB1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.675E-04 | 5.449E-04 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 2.272E-04 | 6.817E-04 | CAMK2B; ACHE; AKT1; MAPK1; PIK3R1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 2.087E-04 | 6.464E-04 | GSK3B; AKT1; PIK3R1; PYGL; NFKB1 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 3.299E-05 | 1.242E-04 | CSNK2A1; SRC; MAPK1; MET; IGF1R |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.088E-05 | 1.186E-04 | CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 2.581E-04 | 7.509E-04 | CAMK2B; SYK; SRC; AKT1; MAPK1; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.752E-05 | 7.158E-05 | CYP2C8; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 3.521E-04 | 9.887E-04 | SYK; SRC; AKT1; MAPK1; PIK3R1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 3.019E-04 | 8.650E-04 | ALOX5; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 3.656E-04 | 9.887E-04 | CAMK2B; AR; CDK1; MAPK1; IGF1R |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 5.054E-04 | 1.311E-03 | SYK; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 4.550E-04 | 1.197E-03 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 7.501E-04 | 1.846E-03 | SYK; CXCR1; AKT1; MAPK1; PIK3R1 |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 7.042E-04 | 1.756E-03 | GSK3B; AKT1; MAPK1; PIK3R1; IGF1R |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 6.393E-04 | 1.615E-03 | GSK3B; AKT1; MAPK1; PIK3R1; PYGL |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.137E-03 | 2.695E-03 | THPO; PIM1; AKT1; STAT6; PIK3R1 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.791E-03 | 3.822E-03 | POLB; GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.785E-03 | 3.822E-03 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.086E-03 | 2.606E-03 | CAMK2B; SRC; MMP2; MAPK1 |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 1.597E-03 | 3.566E-03 | CAMK2B; PKM; AKT1; PYGL |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 1.177E-03 | 2.756E-03 | SYK; AKT1; MAPK1; PIK3R1 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.597E-03 | 3.566E-03 | AKT1; MAPK1; PIK3R1; HIF1A |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 3.608E-04 | 9.887E-04 | SYK; AKT1; MAPK1; PIK3R1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.703E-04 | 5.449E-04 | AKT1; PIK3R1; PTGS2; TSHR |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 8.772E-03 | 1.589E-02 | AKT1; MAPK1; MAPT; TP53; NFKB1 |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 9.343E-03 | 1.646E-02 | CXCR1; SRC; KDR; MET; IGF1R |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 2.227E-04 | 6.787E-04 | AKT1; MAPK1; PIK3R1; HIF1A |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 5.446E-03 | 1.046E-02 | CAMK2B; GSK3B; CSNK2A1; TP53 |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 3.367E-03 | 6.876E-03 | AKT1; PIK3R1; CFTR; IGF1R |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.779E-03 | 3.822E-03 | AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 3.367E-03 | 6.876E-03 | GSK3B; CDK6; CDK1; TP53 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.907E-03 | 4.024E-03 | AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 4.322E-03 | 8.468E-03 | AKT1; MAPK1; PIK3R1; IGF1R |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 1.324E-03 | 3.064E-03 | CA2; PLA2G1B; CD38; CFTR |
| hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 1.025E-02 | 1.772E-02 | CXCR1; THPO; FLT3; KDR; MET |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 2.817E-03 | 5.878E-03 | MMP2; PIK3R1; MMP9; PTK2 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 9.581E-04 | 2.329E-03 | SRC; CDK1; HTR2C; MAPK1 |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 3.667E-03 | 7.412E-03 | GSK3B; MAPK1; MET; PTK2 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 6.751E-03 | 1.234E-02 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 6.295E-03 | 1.162E-02 | CAMK2B; AKT1; MAPK1; PIK3R1 |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 1.231E-02 | 2.092E-02 | CAMK2B; ADORA2A; HTR2C; CD38 |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 6.086E-04 | 1.558E-03 | SRC; PIK3R1; MET; PTK2 |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 2.180E-02 | 3.431E-02 | SRC; MAPK1; PIK3R1; PTK2 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.350E-02 | 2.234E-02 | CSNK2A1; CDK1; TP53; NFKB1 |
| hsa04530 | Tight junction_Homo sapiens_hsa04530 | 3.177E-02 | 4.842E-02 | CSNK2A1; SRC; AKT1 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 3.608E-04 | 9.887E-04 | CXCR1; SRC; MET; NFKB1 |
| hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 2.950E-02 | 4.568E-02 | SYK; MAPK1; PIK3R1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.257E-04 | 1.135E-03 | CA2; CYP3A4; CFTR; ABCG2 |
| hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 2.178E-02 | 3.431E-02 | ADORA2A; PLA2G1B; MAPK1 |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 1.346E-02 | 2.234E-02 | CAMK2B; GSK3B; MAPK1 |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 1.346E-02 | 2.234E-02 | PIK3R1; NFKB1; PTK2 |
| hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 9.527E-03 | 1.663E-02 | THPO; FLT3; CD38 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 8.948E-03 | 1.605E-02 | MAPK1; PKN1; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 5.695E-03 | 1.079E-02 | MAPK1; PTGS2; NFKB1 |
| hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 5.915E-03 | 1.103E-02 | CAMK2B; CA2; CFTR |
| hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 4.866E-03 | 9.438E-03 | CDK6; CDK1; TP53 |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 3.939E-03 | 7.878E-03 | AKT1; PIK3R1; IGF1R |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 4.115E-03 | 8.145E-03 | SRC; MAPK1; NFKB1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 4.502E-05 | 1.662E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 3.245E-02 | 4.906E-02 | MAPK1; NFKB1 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 3.039E-02 | 4.668E-02 | GSK3B; TP53 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.731E-03 | 3.821E-03 | PKM; MAPK1; PIK3R1 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 2.453E-02 | 3.829E-02 | MAOA; NFKB1 |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 2.091E-02 | 3.374E-02 | AKT1; PIK3R1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.180E-02 | 3.431E-02 | CYP3A4; XDH |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 1.345E-03 | 3.074E-03 | ABCC1; CFTR; ABCG2 |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 1.596E-02 | 2.619E-02 | MAPK1; PIK3R1 |
| hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 1.674E-02 | 2.724E-02 | PKM; GLO1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 9.027E-03 | 1.605E-02 | MAPK1; TP53 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 1.159E-02 | 1.987E-02 | POLB; PARP1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 5.735E-03 | 1.079E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.402E-04 | 7.096E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; ACHE; HTR2C; CYP3A4 |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; CA1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
| NA: NA | Primary insomnia | NA | HTR2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; SRC; AURKB; CD38; TP53 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2 |
| NA: NA | Edema | NA | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; MMP12; MMP12; ADORA2A |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; SYK |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; ACHE; ACHE; ACHE; PTGS2; GSK3B; APP |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ADORA2A |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; IGF1R; ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; CA9; HIF1A |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; HTR2C |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; HTR2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; GSK3B; HTR2C |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
| A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; TP53 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TP53; KDR; KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; CA9; IGF1R; CDK1; ESR1; ESR1; KDR; KDR; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; SRC |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | HTR2C |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; AKT1; MET; CSNK2A1; SYK; FLT3; FLT3; CA9; MMP2; ACHE; PTGS2; SRC; IGF1R; PTK2; GSK3B; HIF1A; CDK1; MAPK1; MMP9; NFKB1; PIM1; PARP1; CD38; TP53; ESR1; ESR1; CA1; KDR; APP |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2; NFKB1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13; SYK; MMP12; PTGS2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; CA2 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; AURKB; TP53; TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; PTGS2; XDH |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; ACHE; ADORA2A; CA1; CA1 |
| NA: NA | GIST | NA | FLT3 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioma | C71 | KDR; APP |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; KDR |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; ESR1; ESR1 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3; PARP1 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HTR2C |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; HTR2C; ESR1; APP |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS2; PTGS2; ADORA2A |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC |
| NA: NA | Menopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| C00-D49: Neoplasms | Melanoma | C43 | PARP1; KDR; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; AXL; PTGS2; IGF1R; IGF1R; KDR |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HTR2C; HTR2C |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| NA: NA | Male hypogonadism | NA | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; MMP2; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; SRC; ESR1 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; PARP1; KDR; KDR; KDR; KDR |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| C00-D49: Neoplasms | Multiple myeloma | C90 | SRC; IGF1R; CD38 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR2C; DRD4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; PKM; MMP13; ACHE; PTGS2; PTGS2; PTGS2; PTGS2; IGF1R; ADORA2A; CDK1; HTR2C; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA; HTR2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ALOX5; SYK; MMP3; PTGS2; PTGS2; PTGS2; PTGS2 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2 |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; PKM; SYK; FLT3; CA9; MMP2; SRC; IGF1R; PTK2; AURKB; HIF1A; MAPK1; MMP9; TP53; KDR; KDR; KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
| C00-D49: Neoplasms | AML | NA | FLT3; KDR |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B; ADORA2A |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR2C; DRD4 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; IGF1R; MMP9; TP53; KDR |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; HTR2C; HTR2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ALOX5; ALOX5; SYK; SYK; MMP12; PTGS2; ADORA2A |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ESR1 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE; ADORA2A |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; FLT3; MMP2; PTGS2; KDR |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ESR1 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; MMP12 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ALOX5; PTGS2; PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | PARP1 |